Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Immuno-osseous dysplasia
Immuno-osseous dysplasia
Immuno-osseous dysplasia
Drug discovery
33
papers
On emerging therapies
Rare bone diseases
Immuno-osseous dysplasia
Overview
Schimke immuno-osseous dysplasia (SIOD) is an ultra-rare autosomal recessive disorder caused by biallelic SMARCAL1 mutations, disrupting chromatin remodeling and DNA repair. Key features include spondyloepiphyseal dysplasia (short stature, spinal/hip abnormalities), progressive steroid-resistant nephropathy leading to renal failure, and T-cell immunodeficiency with recurrent infections. Additional manifestations involve cerebrovascular atherosclerosis, migraines, and hypothyroidism [1][2][4][6][16].
Burden
High mortality from infections, renal failure, or strokes (median survival: ~11 years in severe cases) [2][8][13].
Multisystem complications (renal, skeletal, vascular, neurologic) necessitate lifelong multidisciplinary care [1][4][11].
Limited therapeutic efficacy: immunosuppression often fails to halt renal decline, and genotype-phenotype correlations remain unclear [2][8][16].
Therapies
Renal: Kidney transplantation (with mild immunosuppression) and dialysis for end-stage disease [3][8][12].
Immunologic: Prophylactic antivirals, granulocyte colony-stimulating factors, and hematopoietic stem cell transplantation (HSCT) for severe T-cell deficiency [3][6][12].
Symptomatic: Anticoagulation for cerebrovascular events, physical therapy for skeletal issues, and thyroid hormone replacement [3][13][16].
Categories: rare genetic diseases, rare immunological diseases
Research Papers
33 drug discovery papers about Immuno-osseous dysplasia. Recent publications:
33 drug discovery papers about Immuno-osseous dysplasia. Recent publications:
categories:
Small molecules
cell therapies
2026-02-02 | Case Report: Post-transplant lymphoproliferative disorder after kidney transplantation in a child with schimke immuno-osseous dysplasia.
With the inherent T-cell immunodeficiency of Schimke immune-osseous dysplasia (SIOD), the management of immunosuppressive therapy after transplantation and life-threatening infections remains a challenge. Here, we present a case of a child with SIOD who developed early-onset Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after kidney transplantation. PTLD frequently involves the gastrointestinal tract and solid allografts, while this case also involved the lungs, which is extremely rare. This case underscores the importance of considering PTLD in recipients with immunodeficiency, long-term immunosuppressive therapy, and EBV seronegativity. It also suggests low-dose immunotherapy and hematopoietic stem-cell transplantation for patients with SIOD.
2025-12-01 | Successful Use of Haploidentical HSCT in a Child With Schimke Immuno-Osseous Dysplasia Who Developed PTLD After Kidney Transplantation.
Schimke Immuno-Osseous Dysplasia Is a Rare Autosomal Recessive Multisystem Disorder Caused by Biallelic Pathogenic Variants in the SMARCAL1 Gene, Which Encodes a DNA Annealing Helicase Essential for Replication Fork Stability and Genomic Maintenance. Loss of SMARCAL1 Function Leads to Genomic Instability, Resulting in a Characteristic Clinical Triad of Disproportionate Short Stature, Steroid-Resistant Nephrotic Syndrome and Immunodeficiency. Kidney Transplantation Is the Standard Treatment for End-Stage Renal Disease in Schimke Immuno-Osseous Dysplasia. However, the Underlying Genomic Fragility and Immunodeficiency Heighten the Risk of Post-Transplant Complications, Particularly Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder. We Report the Case of a 7-Year-Old Girl With Genetically Confirmed Schimke Immuno-Osseous Dysplasia Who Developed Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Eight Months Following Maternal Kidney Transplantation, Despite Reduced-Intensity Immunosuppression. Rituximab Therapy Resulted in Complete Remission, but Required the Withdrawal of all Immunosuppressive Agents, Thereby Posing a Risk of Kidney Graft Loss. In the Context of Primary Immunodeficiency and the Development of Post-Transplant Lymphoproliferative Disorder in Such a Setting, the Patient Subsequently Underwent Haploidentical Hematopoietic Stem Cell Transplantation From the Mother, Using an αβ T-Cell-Depleted Graft and a Nephrotoxicity-Sparing Conditioning Regimen. Full Donor Chimerism Was Achieved by Day 28. Immune Reconstitution Occurred Within One Year. At 27 Months After Hematopoietic Stem Cell Transplantation She Remains in Remission With Preserved Kidney Function and no Ongoing Immunosuppression. This Case Highlights the Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation as a Curative Salvage Strategy for Immunosuppression-Free Survival After Kidney Transplantation in Patients With Schimke Immuno-Osseous Dysplasia.
2023-12-01 | 13 Successful sequential haploidentical maternal haematopoietic stem cell and kidney transplantation for Schimke immuno-osseous dysplasia
Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive disease caused by homozygous SMARCAL1 gene mutation leading to focal segmental glomerulosclerosis (FSGS), immunodeficiency and disproportionate short stature. The quality and quantity of life improvement relies on management of end-stage kidney disease (ESKD) and prevention of possibly fatal opportunistic infections caused by T-cell deficiency. A five-year-old girl presented with steroid resistant nephrotic syndrome, dysmorphic features and short stature and had genetic confirmation of SIOD. In the year following her diagnosis, she reached ESKD and commenced haemodialysis (HD). The possibility of proceeding with maternal stem cell then kidney transplant from the same haploidentical donor was accepted by the hospital's ethic committee. She underwent conditioning treatment with pharmacokinetic adjusted chemotherapy followed by successful engraftment of the αβ T-cell– and CD19 B-cell–depleted haematopoietic stem cell transplantation (HSCT) at seven-years-old. She was switched from HD to continuous veno-venous haemofiltration (CVVH) for 24 days to sustain strict fluid control as chemotherapy and nutrition were given intravenously. She developed mucositis and mild skin graft versus host disease which resolved at discharge 40 days after conditioning had begun. The 175-day period between HSCT and living-related kidney transplantation (LRKT) was uneventful. She underwent LRKT with no human leukocyte antigen (HLA) mismatch, no induction or anti-proliferative agents and low trough tacrolimus levels. She recovered normal kidney function five days post-transplant and remains stable with a median eGFR of 125 ml/min/1.73m2 with discontinuation of all immunosuppressive therapy since then. Her infectious prophylaxis regimen included oral letermovir, aciclovir, co-trimoxazole and itraconazole. Haploidentical HSCT prior to LRKT is a high-risk intervention which could improve life expectancy in patients with SIOD. To our knowledge, we are the first team to demonstrate the success of the Stanford protocol in a paediatric recipient receiving CVVH during HSCT conditioning treatment. This intervention led to a successful LRKT with minimal immunosuppression, which was the first case performed in our centre.
Acknowledgements for funding or support
C. Laroche received funds from Sainte-Justine University Hospital, Montreal, to carry out her work at GOSH
2022-06-17 | Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia.
Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune rejection and the need for post-transplantation immunosuppression in three patients with Schimke immuno-osseous dysplasia who had both T-cell immunodeficiency and renal failure. Each patient received sequential transplants of αβ T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney from the same donor. Full donor hematopoietic chimerism and functional ex vivo T-cell tolerance was achieved, and the patients continued to have normal renal function without immunosuppression at 22 to 34 months after kidney transplantation. (Funded by the Kruzn for a Kure Foundation.).
2019-06-01 | GP61 Swollen eyes with an unpleasant surprise – a case report of a steroid resistant nephrotic syndrome
With a reported incidence of 7:100 000, nephrotic syndrome (NS) is one of the more common nephrology disorders that can present to and is often treated by the general paediatrician in a primary and secondary level hospital. Standard treatment consists of steroids. Steroid resistant NS (SRNS) is an indication for renal biopsy. We present a case of a 5-year-old girl, who presented to a regional hospital at the age of 2.5 years, with periorbital oedema and abdominal swelling. Her medical history was significant for premature delivery, history of Intrauterine Growth Restriction (IUGR) and postnatal failure to thrive, persistent leucopoenia and mild developmental delay. Upon presentation she had marked proteinuria, serum hypoalbuminemia and hyperlipidaemia. A diagnosis of NS was made but she failed to respond to standard steroid treatment. She was transferred to a tertiary hospital on day 26 of admission with a suspicion of thrombophlebitis of her left lower limb. There, she was noted to have low set ears, areas of hyperpigmentation on her trunk, periorbital and limb oedema, ascites and abnormal posture. Pelvic X-ray showed bilateral hip dysplasia. Eye exam revealed retinal degeneration and blood investigations noted hypogammaglubulinemia, low CD4 and CD8 lymphocytes and high TSH. In view of her clinical picture, steroid resistant NS and leucopoenia, Shimke Immuno-Osseous dysplasia (SIOD) was suspected. SIOD is a rare autosomal recessive disease consisting of renal failure, skeletal dysplasia and T-cell deficiency. This was subsequently confirmed by genetic testing which showed 2 pathogenic mutations within the SMARCAL 1 gene. Overtime she progressed to end stage renal disease, and initiated peritoneal dialysis within a year of diagnosis. She remains to date without any major infectious, central nervous system (CNS) or autoimmune complications commonly seen in SIOD. The majority of paediatric patients with NS respond to steroid treatment. A subset of children might however have clinical and biochemical features or a family history predictive of a steroid resistant NS. Recent advances in molecular genetics identified underlying genetic cause in a large proportion of patients with SRNS. These children might benefit from an early referral to a tertiary centre in order to accelerate the diagnosis, potentially avoid renal biopsy and limit the exposure to steroids, which won’t improve their condition. Rather they might increase their already elevated risk of infection and other complications.
small molecules
2025-12-10 | Myasthenia Gravis in a Child With Schimke Immuno-Osseous Dysplasia: A Case Report.
We report a rare association between Schimke immune-osseous dysplasia and myasthenia gravis. Clinicians should be aware of potential autoimmune neuromuscular complications in SIOD, as early recognition and tailored immunosuppression may improve prognosis.
2023-04-12 | Successful low‐dose immunotherapy after kidney transplantation in a 10‐year‐old girl with Schimke immuno‐osseous dysplasia
Abstract Background This case report highlights a successful steroid‐free, low‐dose immunosuppressive protocol for renal transplantation in a pediatric patient with Schimke immuno‐osseous dysplasia with excellent 7‐year patient and graft survival. Schimke immuno‐osseous dysplasia is a rare multisystem disorder involving the kidney. Renal transplantation is a therapeutic option, but posttransplant mortality is high due to severe infections and posttransplant lymphoproliferative disease. Methods A 10‐year‐old girl diagnosed with Schimke immuno‐osseous dysplasia and end‐stage renal disease underwent an AB0‐compatible living‐related kidney transplantation, with no donor‐specific antibodies. Our standard immunosuppression protocol was modified due to the risk of infection. Basiliximab was used as induction therapy, and a reduced dose of mycophenolate mofetil and tacrolimus was initiated following transplantation, maintaining the patient on a low tacrolimus target (3–5 μg/L). Mycophenolate mofetil was discontinued after 8 weeks due to neutropenia and the patient was kept on tacrolimus as monotherapy. Five years posttransplant the patient developed acute onset of neurological symptoms, consisting of ataxia, lack of voluntary coordination, balance, aphasia and dysphagia, and diplopia. She recovered without neurological deficits within 6 weeks. Extensive evaluation revealed no pathology. To avoid a possible a component of tacrolimus‐induced cerebral vasoconstriction, the immunosuppressive therapy was changed to everolimus. Results Seven years posttransplant, the patient has experienced no serious infections, no rejections, and had excellent graft function, and no de novo donor‐specific antibodies. Conclusions The present results indicate that low‐dose immunosuppressive therapy after renal transplantation with low immunological risk should be considered for patients with Schimke immuno‐osseous dysplasia.
2019-02-25 | BK virus associated nephropathy and severe pneumonia in a kidney transplanted adolescent with Schimke immuneosseous- dysplasia
Düzova A, Gülhan B, Topaloğlu R, Özaltın F, Cengiz AB, Yetimakman AF, Doğru D, Güçer Ş, Beşbaş N. BK virus associated nephropathy and severe pneumonia in a kidney transplanted adolescent with Schimke immune-osseous-dysplasia. Turk J Pediatr 2019; 61: 111-116. Patients with juvenile onset Schimke immune-osseous-dysplasia (SIOD) have less severe symptoms and can survive in the second and third decade of life. We present an 18 year-old adolescent with juvenile onset SIOD who was diagnosed after renal transplantation and developed BK virus associated nephropathy (BKVAN) and severe pneumonia during follow-up. The patient developed nephrotic syndrome, unresponsive to immunosuppressives, at the age of 8 years. He had a history of meningitis, short stature, microcephaly, prominent ears, and bilateral cryptorchidism. A renal transplantation was performed at the age of 15 years. During follow-up, he suffered from leucopenia, urinary tract infections, herpes labialis, and candida esophagitis. Sanger sequencing of SMARCAL1 revealed a missense mutation on exon 11 (R586W). A renal biopsy performed after a sharp increase in serum creatinine (without significant viremia) revealed BKVAN which responded to sirolimus monotherapy and cidofovir. Three months later, he suffered from productive cough and dyspnea with diffuse ground glass pulmonary infiltrates. His clinical situation deteriorated and non-invasive mechanical ventilation was started. Cidofovir (2 mg/kg) was re-started weekly for a possible BKV pneumonia with intravenous immunoglobulin. After 5 doses of cidofovir and intense antibiotic regime, his dyspnea resolved with stable graft functions. In our case; BKVAN, which developed without significant viremia, and possibly associated pneumonia were treated successfully with cidofovir and sirolimus monotherapy.
2018-11-22 | Reversible Cerebral Vasoconstriction Syndrome: A Novel Mechanism for Neurological Complications in Schimke Immuno-osseous Dysplasia
Background Schimke immuno-osseous dysplasia is a rare autosomal recessive disease resulting from biallelic SMARCAL1 mutations. It presents in early childhood and is characterized by short stature, nephropathy, and immunodeficiency. Approximately 50% of those affected have neurological complications including migraines, transient ischemic attacks, and strokes. Methods We present a six-year-old boy with Schimke immuno-osseous dysplasia without evidence of atherosclerosis with recurrent episodes of severe headache, fluctuating hemiparesis, and aphasia. Results Magnetic resonance imaging and angiography were normal during the initial episode; multiple areas of reversible restricted diffusion with decreased perfusion and arterial stenosis were seen with subsequent attacks. Conclusions This constellation of symptoms and imaging findings is suggestive of reversible cerebral vasoconstriction syndrome, which we propose as a mechanism for the transient ischemic attacks and infarcts seen in some patients with Schimke immuno-osseous dysplasia, as opposed to accelerated atherosclerosis alone. This new insight may provide a basis for novel preventative therapy in this rare disorder.
2016-11-05 | Increased Wnt and Notch signaling: a clue to the renal disease in Schimke immuno-osseous dysplasia?
Schimke immuno-osseous dysplasia (SIOD) is a multisystemic disorder caused by biallelic mutations in the SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily A-like 1 (SMARCAL1) gene. Changes in gene expression underlie the arteriosclerosis and T-cell immunodeficiency of SIOD; therefore, we hypothesized that SMARCAL1 deficiency causes the focal segmental glomerulosclerosis (FSGS) of SIOD by altering renal gene expression. We tested this hypothesis by gene expression analysis of an SIOD patient kidney and verified these findings through immunofluorescent analysis in additional SIOD patients and a genetic interaction analysis in Drosophila. We found increased expression of components and targets of the Wnt and Notch signaling pathways in the SIOD patient kidney, increased levels of unphosphorylated β-catenin and Notch1 intracellular domain in the glomeruli of most SIOD patient kidneys, and genetic interaction between the Drosophila SMARCAL1 homologue Marcal1 and genes of the Wnt and Notch signaling pathways. We conclude that increased Wnt and Notch activity result from SMARCAL1 deficiency and, as established causes of FSGS, contribute to the renal disease of most SIOD patients. This further clarifies the pathogenesis of SIOD and will hopefully direct potential therapeutic approaches for SIOD patients.
gene therapies
2026-08-20 | Beyond Defense: Kidney Mysteries in Inborn Errors of Immunity
Inborn errors of immunity (IEI), formerly termed primary immunodeficiencies, are increasingly recognized as disorders of immune dysregulation rather than infection susceptibility alone. With over 500 validated genes in the 2024 International Union of Immunological Societies (IUIS) classification and approximately one-quarter of patients presenting without infection, autoimmunity, autoinflammation, lymphoproliferation, and malignancy are now core features. The kidney is affected across at least 22 IEI categories, yet renal involvement remains under-recognized. This review proposes a mechanistic framework for IEI-associated kidney disease, encompassing: complement dysregulation (C3 glomerulopathy, atypical hemolytic uremic syndrome from CFH/CFI/C3 variants); immune complex–mediated and monogenic lupus nephritis (C1q, C2, C4, DNASE1L3, and TREX1 defects); autoinflammatory and type I interferonopathy–driven nephropathy; infection-related glomerulonephritis (common variable immunodeficiency [CVID], chronic granulomatous disease); lymphoproliferative and immune-dysregulation syndromes causing interstitial nephritis (ALPS, CTLA-4 and LRBA deficiency); and syndromic IEI with intrinsic structural disease. We outline a stepwise diagnostic approach integrating clinical red flags, complement and immune profiling, kidney biopsy with immunofluorescence and electron microscopy, and genetic testing, emphasizing that genetic diagnosis should precede immunosuppression. The therapeutic landscape is shifting from empirical immunosuppression toward precision medicine, including complement inhibitors (iptacopan, pegcetacoplan, Food and Drug Administration–approved for C3 glomerulopathy in 2025), JAK inhibitors for interferonopathies, leniolisib for activated PI3Kδ syndrome, CTLA4-Ig agents, and curative hematopoietic stem cell transplantation and emerging gene therapy. An illustrative case from Europe’s largest kidney transplant center illustrates a girl with Schimke immuno-osseous dysplasia (SMARCAL1 mutation) presenting with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis who underwent kidney transplantation following bone marrow transplant. Recognizing IEI in unexplained nephropathy, combining biopsy with complement and genetic profiling, and early nephrology–immunology collaboration are key to improving renal outcomes and enabling potentially curative therapy.
2026-03-06 | Genetic alterations in Schimke immunoosseous dysplasia: Pathogenic mechanisms and therapeutic prospects
Schimke immuno-osseous dysplasia (SIOD) is an ultra-rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in SMARCAL1, which encodes an adenosine triphosphate-dependent annealing helicase involved in replication-fork remodeling and chromatin dynamics. Loss of SMARCAL1 function leads to replication-associated genomic instability, transcriptional dysregulation, and telomere dysfunction, collectively underlying the triad of steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency, as well as vascular and malignant complications. In this review, we summarize the spectrum of SMARCAL1 genetic alterations in SIOD, ranging from missense and truncating variants to gross deletions, and discuss their molecular consequences at the protein and cellular levels. We highlight current disease models, including patient-derived induced pluripotent stem cells (iPSCs) and inducible SMARCAL1 knockdown iPSC systems, which have revealed mechanistic links between replication stress and dysregulated expression of master differentiation genes. Finally, we evaluate the state of the art and realistic prospects for gene therapy in SIOD. Although no gene therapy trial for SIOD is currently active, advances in iPSC modeling, clustered regularly interspaced short palindromic repeats-mediated gene correction, and successful ex vivo hematopoietic stem cell gene therapy in related monogenic immunodeficiencies position SMARCAL1 as a plausible, though challenging, therapeutic target. Key obstacles include multi-organ involvement, strict control of SMARCAL1 dosage due to its role in genome stability, and the extreme rarity of the disorder, which limits the feasibility of clinical trials.
2025-02-26 | Genetic and Clinical Features of Schimke Immuno-Osseous Dysplasia: Single-Centre Retrospective Study of 21 Unrelated Paediatric Patients over a Period of 20 Years.
Schimke immuno-osseous dysplasia (SIOD) is a hereditary autosomal-recessive multi-system disorder with early mortality. It has variable clinical presentations, mainly characterised by disproportional short stature, steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency. In the majority of cases, SIOD is caused by pathogenic sequence variants (PSVs) in the SMARCAL1 gene that encodes protein involved in chromatin remodelling. SIOD is an ultra-rare condition, with an incidence of ~1 per 1-3 million live births; data on its genetic and clinical features are scarce. We conducted a retrospective study of 21 paediatric patients with SIOD diagnosed in our centre during the years 2003-2023. The most common extra-renal clinical features were short stature, osseous dysplasia, multiple stigmas, and leukopenia. Proteinuria of varying severity was observed in 16 cases. The five-year overall survival rate (OS) was 89% (95% CI 77-100%), and the ten-year OS was 10%. Next-generation sequencing (NGS) revealed the following PSVs in SMARCAL1 in 19 patients: c.355_500del, c.2542G>T, c.2290C>T, c.2562del, c.2533_2534del, c.1582A>C, c.1933C>T, c.1010T>C, c.1736C>T, c.2070dup, c.2551A>T, c.2149_2150dup, c.939delC, and c.1451T>A; the most common was c.2542G>T, resulting in premature translation termination (p.E848*), and it was found in 14 patients either in a homozygous (four patients) or compound-heterozygous (10 patients) state. According to microsatellite analysis, it is a "founder mutation" in Russia.
2010-05-01 | SMARCAL1 and replication stress
The SNF2 family of ATPases acts in the context of chromatin to regulate transcription, replication, repair, and recombination. Defects in SNF2 genes cause many human diseases. For example, mutations in SMARCAL1 (also named HARP) cause Schimke immuno-osseous dysplasia (SIOD); a multi-system disorder characterized by growth defects, immune deficiencies, renal failure and other complex phenotypes. Several groups including ours recently identified SMARCAL1 as a replication stress response protein. Importantly, SMARCAL1 localizes to stalled replication forks and this localization of SMARCAL1 activity prevents DNA damage accumulation during DNA replication. We determined that SIOD-related SMARCAL1 mutants could not prevent replication-associated DNA damage in cells in which endogenous SMARCAL1 was silenced, establishing the first link between SIOD and a defect in a specific biological activity. Here, we also report that cells from patients with SIOD exhibit elevated levels of DNA damage that can be rescued by re-introduction of wild-type SMARCAL1. Our data suggest that loss of SMARCAL1 function in patients may cause DNA replication-associated genome instability that contributes to the pleiotropic phenotypes of SIOD.
antibodies
2026-01-01 | When rarity meets complexity - Schimke immuno-osseous dysplasia with nephrotic syndrome: a 15-year longitudinal case report
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder caused by pathogenic variants in the SMARCAL1 gene and characterised by spondyloepiphyseal dysplasia, immunodeficiency, and progressive renal disease, often presenting as steroid-resistant nephrotic syndrome.Fewer than 100 cases have been reported worldwide.This manuscript describes a male patient with genetically confirmed SIOD, monitored age 4.5-19 years.Early features included growth failure, hyperpigmentation, skeletal abnormalities, moderate T-cell lymphopaenia, and biopsy-proven focal segmental glomerulosclerosis.In adolescence, the disease transitioned to a severe phenotype with end-stage renal disease, recurrent infections, bone marrow failure, and Evans syndrome, reflecting profound immune dysregulation.Despite multidisciplinary management, including renal-replacement therapy and individualised immunological care, the patient's condition progressively deteriorated and he ultimately died from multi-organ failure.This long-term observation illustrates the evolving natural history of SIOD and the shift from renal disease in childhood to combined immunodeficiency and haematological complications in adolescence.
2025-12-26 | Clinical and genetic characteristics of Schimke immuno-osseous dysplasia in Russian children: a single-centre study
.
2025-06-11 | Schimke immune-osseous dysplasia at the junction of specialties. A clinical case of disease diagnosis by allergologists and immunologists
Introduction. Schimke immuno-osseous dysplasia (SIOD) is an autosomal recessive, ultrarare disorder characterized by multisystem involvement accompanied by spondyloepiphyseal dysplasia of the skeleton, steroid-resistant proteinuric nephropathy leading to progressive loss of renal function, impaired immunity, and vascular damage caused by atherosclerosis. SIOD is caused by biallelic pathogenic variations in the SMARCAL1 gene.The clinical manifestations of SIOD are very diverse: from a rapidly progressive disease in which children die in the first years of life, to milder forms in which they survive to adulthood. The correlation between genotype and phenotype is extremely weak, so it is impossible to predict either the clinical course or the outcome of the disease. For this reason, patients with this pathology can be seen by various specialists. Case report. The publication presents a clinical case of a 4-year-old boy with immunological deficiency, developmental disorders, and skeletal anomalies, indicating in favor of SIOD.Whole exome sequencing in the SMARCAL1 gene revealed mutation variants с.2542G>T (p.Glu848Ter); c.1682G>T (p.Arg561Leu) in a heterozygous state.Based on the results of the genetic study, and also taking into account that the disease is multisystemic, the child was examined by a nephrologist, orthopedist, endocrinologist and geneticist.Conclusions of the nephrologist: glomerulopathy in Schimke syndrome: isolated proteinuria. Left calicectasis. Chronic kidney disease (CKD), stage 2. Glomerular filtration rate (Schwartz test) — 69.01 ml/min/1.73 m2.Endocrinologist’s conclusion: syndromic short stature. Protein-energy malnutrition grade 2.A telemedicine consultation was conducted with the Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology and Oncology named after D. Rogachev, based on the results of which replacement therapy with intravenous or subcutaneous immunoglobulins was recommended, as well as hospitalization in the immunology department of this federal center. Conclusion. This description is the first case of diagnostics of an ultrarare disease (1:1–3,000,000 live births) in Krasnodar region by regional specialists. In this patient, the course of the disease is characterized by a non-severe, non-progressive renal dysfunction, which gives reason to assume a milder form of the disease. Conducting replacement therapy with immunoglobulins makes it possible to improve the prognosis in this patient.
2021-05-31 | Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency.
Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency. We report 2 patients with BCP-ALL and congenital T-cell immunodeficiency, who obtained an excellent response to blinatumomab. The first, a 6-year-old girl with Schimke immuno-osseous dysplasia (SIOD) and combined immunodeficiency disorder (CID) obtained a minimum residual disease-negative (MRD-) remission of high hyperdiploid BCP-ALL with blinatumomab. At last follow-up, the remission had been sustained for 14 months from diagnosis. The second was a 9-year-old boy with Omenn syndrome and CID who received a mismatched bone marrow transplant from his mother at the age of 4 months and was diagnosed with t(3;11)+ (KMT2A-LARS2) BCP-ALL 9 years after his transplant. He received a 4-drug induction followed by blinatumomab for persistent MRD as a chemotherapy-sparing bridge to transplant and achieved an MRD- remission. T-lymphopenia, whether congenital or acquired, does not compromise the efficacy of blinatumomab.
other
2025-11-09 | A novel gross deletion in SMARCAL1 impairs DNA replication fork regression, leading to severe Schimke immuno-osseous dysplasia; a literature review and an integrated study of clinical, genetic, and protein-protein interaction analysis
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder that affects multiple organ systems, most notably the skeletal system, kidneys, and immune system. The clinical manifestations of SIOD include growth retardation, skeletal deformities, progressive proteinuria, and immunodeficiency. Severe cases may progress to nephrotic syndrome and cerebral infarctions. The disorder is primarily attributed to biallelic mutations in the SMARCAL1 gene, which leads to the early onset of symptoms and often results in premature mortality. In this study, we identified a novel gross deletion encompassing exons 5 and 6 of the SMARCAL1 gene. This deletion leads to a partial loss of the HARP1 and HARP2 domains and the generation of a novel HARP domain that is structurally similar to both HARP1 and HARP2, while retaining conserved amino acids. Our AlphaFold 3D modeling indicated that the truncated SMARCAL1 protein is identical to the wild-type SMARCAL1, except for the absence of HARP1 domain, and resembles invertebrate SMARCAL1, which naturally possesses only one HARP domain. Previous studies have demonstrated that human SMARCAL1 lacking the HARP1 domain retains normal helicase, ATPase, and DNA-binding activities. Additionally, invertebrate SMARCAL1, which also lacks the HARP1 domain, fails to effectively regress DNA replication forks. This suggests that the identified gross deletion may contribute to SIOD pathogenesis by impairing DNA replication fork regression and genomic instability
2024-09-18 | Different growth patterns in two siblings with Schimke immuno-osseous-dysplasia.
Schimke immuno-osseous-dysplasia (SIOD) is an autosomal recessive systemic disease due to pathogenic variants in SMARCAL1. Manifestations include nephrotic syndrome (NS), kidney failure, T-cell dysfunction, vaso-occlusive disease, and disproportionate short stature, a general feature of this disease. Here, we present a markedly different growth pattern in two brothers with SIOD sharing the same homozygous R561C missense variant. The index patient presented at the age of 11 years with NS and severely disproportionate short stature, followed by kidney failure at the age of 16, and severely reduced adult height (z-score - 8.0). In contrast, the younger brother showed normal growth until the age of 8 years. Mild proteinuria was noted at the age of 4.5, followed by NS at 9.5 years, kidney failure at 11 years, progressive disproportionate stature, and reduced adult height (z-score - 4.5). Both brothers had comparable disproportion in adulthood (sitting height index z-score - 0.88 and - 1.44, respectively).
2024-08-08 | Expanding the Clinical Features of Schimke Immuno-osseous Dysplasia: a New Patient with a Novel Variant and Novel Clinical Findings.
Schimke immuno-osseous dysplasia (SIOD) (MIM:242900) is an ultra-rare, autosomal recessive, pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency, spondyloepiphyseal dysplasia (SED) and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-a-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia, and elevated follicle-stimulating hormone (FSH) levels. Karyotype analysis and array-CGH testing were normal. Clinical exome sequencing (CES) was performed to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious SED was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. The literature on SMARCAL1 gene pathogenic variants, including 125 SIOD cases from 38 articles was reviewed to investigate whether hypercalcemia, hypophosphatemia, and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first report of these findings in a patient with SIOD. Thus, this report expands both the phenotypic and genotypic spectrum of SIOD.
cell therapies
2026-02-02 | Case Report: Post-transplant lymphoproliferative disorder after kidney transplantation in a child with schimke immuno-osseous dysplasia.
With the inherent T-cell immunodeficiency of Schimke immune-osseous dysplasia (SIOD), the management of immunosuppressive therapy after transplantation and life-threatening infections remains a challenge. Here, we present a case of a child with SIOD who developed early-onset Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after kidney transplantation. PTLD frequently involves the gastrointestinal tract and solid allografts, while this case also involved the lungs, which is extremely rare. This case underscores the importance of considering PTLD in recipients with immunodeficiency, long-term immunosuppressive therapy, and EBV seronegativity. It also suggests low-dose immunotherapy and hematopoietic stem-cell transplantation for patients with SIOD.
2025-12-01 | Successful Use of Haploidentical HSCT in a Child With Schimke Immuno-Osseous Dysplasia Who Developed PTLD After Kidney Transplantation.
Schimke Immuno-Osseous Dysplasia Is a Rare Autosomal Recessive Multisystem Disorder Caused by Biallelic Pathogenic Variants in the SMARCAL1 Gene, Which Encodes a DNA Annealing Helicase Essential for Replication Fork Stability and Genomic Maintenance. Loss of SMARCAL1 Function Leads to Genomic Instability, Resulting in a Characteristic Clinical Triad of Disproportionate Short Stature, Steroid-Resistant Nephrotic Syndrome and Immunodeficiency. Kidney Transplantation Is the Standard Treatment for End-Stage Renal Disease in Schimke Immuno-Osseous Dysplasia. However, the Underlying Genomic Fragility and Immunodeficiency Heighten the Risk of Post-Transplant Complications, Particularly Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder. We Report the Case of a 7-Year-Old Girl With Genetically Confirmed Schimke Immuno-Osseous Dysplasia Who Developed Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Eight Months Following Maternal Kidney Transplantation, Despite Reduced-Intensity Immunosuppression. Rituximab Therapy Resulted in Complete Remission, but Required the Withdrawal of all Immunosuppressive Agents, Thereby Posing a Risk of Kidney Graft Loss. In the Context of Primary Immunodeficiency and the Development of Post-Transplant Lymphoproliferative Disorder in Such a Setting, the Patient Subsequently Underwent Haploidentical Hematopoietic Stem Cell Transplantation From the Mother, Using an αβ T-Cell-Depleted Graft and a Nephrotoxicity-Sparing Conditioning Regimen. Full Donor Chimerism Was Achieved by Day 28. Immune Reconstitution Occurred Within One Year. At 27 Months After Hematopoietic Stem Cell Transplantation She Remains in Remission With Preserved Kidney Function and no Ongoing Immunosuppression. This Case Highlights the Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation as a Curative Salvage Strategy for Immunosuppression-Free Survival After Kidney Transplantation in Patients With Schimke Immuno-Osseous Dysplasia.
2023-12-01 | 13 Successful sequential haploidentical maternal haematopoietic stem cell and kidney transplantation for Schimke immuno-osseous dysplasia
Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive disease caused by homozygous SMARCAL1 gene mutation leading to focal segmental glomerulosclerosis (FSGS), immunodeficiency and disproportionate short stature. The quality and quantity of life improvement relies on management of end-stage kidney disease (ESKD) and prevention of possibly fatal opportunistic infections caused by T-cell deficiency. A five-year-old girl presented with steroid resistant nephrotic syndrome, dysmorphic features and short stature and had genetic confirmation of SIOD. In the year following her diagnosis, she reached ESKD and commenced haemodialysis (HD). The possibility of proceeding with maternal stem cell then kidney transplant from the same haploidentical donor was accepted by the hospital's ethic committee. She underwent conditioning treatment with pharmacokinetic adjusted chemotherapy followed by successful engraftment of the αβ T-cell– and CD19 B-cell–depleted haematopoietic stem cell transplantation (HSCT) at seven-years-old. She was switched from HD to continuous veno-venous haemofiltration (CVVH) for 24 days to sustain strict fluid control as chemotherapy and nutrition were given intravenously. She developed mucositis and mild skin graft versus host disease which resolved at discharge 40 days after conditioning had begun. The 175-day period between HSCT and living-related kidney transplantation (LRKT) was uneventful. She underwent LRKT with no human leukocyte antigen (HLA) mismatch, no induction or anti-proliferative agents and low trough tacrolimus levels. She recovered normal kidney function five days post-transplant and remains stable with a median eGFR of 125 ml/min/1.73m2 with discontinuation of all immunosuppressive therapy since then. Her infectious prophylaxis regimen included oral letermovir, aciclovir, co-trimoxazole and itraconazole. Haploidentical HSCT prior to LRKT is a high-risk intervention which could improve life expectancy in patients with SIOD. To our knowledge, we are the first team to demonstrate the success of the Stanford protocol in a paediatric recipient receiving CVVH during HSCT conditioning treatment. This intervention led to a successful LRKT with minimal immunosuppression, which was the first case performed in our centre.
Acknowledgements for funding or support
C. Laroche received funds from Sainte-Justine University Hospital, Montreal, to carry out her work at GOSH
2022-06-17 | Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia.
Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune rejection and the need for post-transplantation immunosuppression in three patients with Schimke immuno-osseous dysplasia who had both T-cell immunodeficiency and renal failure. Each patient received sequential transplants of αβ T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney from the same donor. Full donor hematopoietic chimerism and functional ex vivo T-cell tolerance was achieved, and the patients continued to have normal renal function without immunosuppression at 22 to 34 months after kidney transplantation. (Funded by the Kruzn for a Kure Foundation.).
2019-06-01 | GP61 Swollen eyes with an unpleasant surprise – a case report of a steroid resistant nephrotic syndrome
With a reported incidence of 7:100 000, nephrotic syndrome (NS) is one of the more common nephrology disorders that can present to and is often treated by the general paediatrician in a primary and secondary level hospital. Standard treatment consists of steroids. Steroid resistant NS (SRNS) is an indication for renal biopsy. We present a case of a 5-year-old girl, who presented to a regional hospital at the age of 2.5 years, with periorbital oedema and abdominal swelling. Her medical history was significant for premature delivery, history of Intrauterine Growth Restriction (IUGR) and postnatal failure to thrive, persistent leucopoenia and mild developmental delay. Upon presentation she had marked proteinuria, serum hypoalbuminemia and hyperlipidaemia. A diagnosis of NS was made but she failed to respond to standard steroid treatment. She was transferred to a tertiary hospital on day 26 of admission with a suspicion of thrombophlebitis of her left lower limb. There, she was noted to have low set ears, areas of hyperpigmentation on her trunk, periorbital and limb oedema, ascites and abnormal posture. Pelvic X-ray showed bilateral hip dysplasia. Eye exam revealed retinal degeneration and blood investigations noted hypogammaglubulinemia, low CD4 and CD8 lymphocytes and high TSH. In view of her clinical picture, steroid resistant NS and leucopoenia, Shimke Immuno-Osseous dysplasia (SIOD) was suspected. SIOD is a rare autosomal recessive disease consisting of renal failure, skeletal dysplasia and T-cell deficiency. This was subsequently confirmed by genetic testing which showed 2 pathogenic mutations within the SMARCAL 1 gene. Overtime she progressed to end stage renal disease, and initiated peritoneal dialysis within a year of diagnosis. She remains to date without any major infectious, central nervous system (CNS) or autoimmune complications commonly seen in SIOD. The majority of paediatric patients with NS respond to steroid treatment. A subset of children might however have clinical and biochemical features or a family history predictive of a steroid resistant NS. Recent advances in molecular genetics identified underlying genetic cause in a large proportion of patients with SRNS. These children might benefit from an early referral to a tertiary centre in order to accelerate the diagnosis, potentially avoid renal biopsy and limit the exposure to steroids, which won’t improve their condition. Rather they might increase their already elevated risk of infection and other complications.
small molecules
2025-12-10 | Myasthenia Gravis in a Child With Schimke Immuno-Osseous Dysplasia: A Case Report.
We report a rare association between Schimke immune-osseous dysplasia and myasthenia gravis. Clinicians should be aware of potential autoimmune neuromuscular complications in SIOD, as early recognition and tailored immunosuppression may improve prognosis.
2023-04-12 | Successful low‐dose immunotherapy after kidney transplantation in a 10‐year‐old girl with Schimke immuno‐osseous dysplasia
Abstract Background This case report highlights a successful steroid‐free, low‐dose immunosuppressive protocol for renal transplantation in a pediatric patient with Schimke immuno‐osseous dysplasia with excellent 7‐year patient and graft survival. Schimke immuno‐osseous dysplasia is a rare multisystem disorder involving the kidney. Renal transplantation is a therapeutic option, but posttransplant mortality is high due to severe infections and posttransplant lymphoproliferative disease. Methods A 10‐year‐old girl diagnosed with Schimke immuno‐osseous dysplasia and end‐stage renal disease underwent an AB0‐compatible living‐related kidney transplantation, with no donor‐specific antibodies. Our standard immunosuppression protocol was modified due to the risk of infection. Basiliximab was used as induction therapy, and a reduced dose of mycophenolate mofetil and tacrolimus was initiated following transplantation, maintaining the patient on a low tacrolimus target (3–5 μg/L). Mycophenolate mofetil was discontinued after 8 weeks due to neutropenia and the patient was kept on tacrolimus as monotherapy. Five years posttransplant the patient developed acute onset of neurological symptoms, consisting of ataxia, lack of voluntary coordination, balance, aphasia and dysphagia, and diplopia. She recovered without neurological deficits within 6 weeks. Extensive evaluation revealed no pathology. To avoid a possible a component of tacrolimus‐induced cerebral vasoconstriction, the immunosuppressive therapy was changed to everolimus. Results Seven years posttransplant, the patient has experienced no serious infections, no rejections, and had excellent graft function, and no de novo donor‐specific antibodies. Conclusions The present results indicate that low‐dose immunosuppressive therapy after renal transplantation with low immunological risk should be considered for patients with Schimke immuno‐osseous dysplasia.
2019-02-25 | BK virus associated nephropathy and severe pneumonia in a kidney transplanted adolescent with Schimke immuneosseous- dysplasia
Düzova A, Gülhan B, Topaloğlu R, Özaltın F, Cengiz AB, Yetimakman AF, Doğru D, Güçer Ş, Beşbaş N. BK virus associated nephropathy and severe pneumonia in a kidney transplanted adolescent with Schimke immune-osseous-dysplasia. Turk J Pediatr 2019; 61: 111-116. Patients with juvenile onset Schimke immune-osseous-dysplasia (SIOD) have less severe symptoms and can survive in the second and third decade of life. We present an 18 year-old adolescent with juvenile onset SIOD who was diagnosed after renal transplantation and developed BK virus associated nephropathy (BKVAN) and severe pneumonia during follow-up. The patient developed nephrotic syndrome, unresponsive to immunosuppressives, at the age of 8 years. He had a history of meningitis, short stature, microcephaly, prominent ears, and bilateral cryptorchidism. A renal transplantation was performed at the age of 15 years. During follow-up, he suffered from leucopenia, urinary tract infections, herpes labialis, and candida esophagitis. Sanger sequencing of SMARCAL1 revealed a missense mutation on exon 11 (R586W). A renal biopsy performed after a sharp increase in serum creatinine (without significant viremia) revealed BKVAN which responded to sirolimus monotherapy and cidofovir. Three months later, he suffered from productive cough and dyspnea with diffuse ground glass pulmonary infiltrates. His clinical situation deteriorated and non-invasive mechanical ventilation was started. Cidofovir (2 mg/kg) was re-started weekly for a possible BKV pneumonia with intravenous immunoglobulin. After 5 doses of cidofovir and intense antibiotic regime, his dyspnea resolved with stable graft functions. In our case; BKVAN, which developed without significant viremia, and possibly associated pneumonia were treated successfully with cidofovir and sirolimus monotherapy.
2018-11-22 | Reversible Cerebral Vasoconstriction Syndrome: A Novel Mechanism for Neurological Complications in Schimke Immuno-osseous Dysplasia
Background Schimke immuno-osseous dysplasia is a rare autosomal recessive disease resulting from biallelic SMARCAL1 mutations. It presents in early childhood and is characterized by short stature, nephropathy, and immunodeficiency. Approximately 50% of those affected have neurological complications including migraines, transient ischemic attacks, and strokes. Methods We present a six-year-old boy with Schimke immuno-osseous dysplasia without evidence of atherosclerosis with recurrent episodes of severe headache, fluctuating hemiparesis, and aphasia. Results Magnetic resonance imaging and angiography were normal during the initial episode; multiple areas of reversible restricted diffusion with decreased perfusion and arterial stenosis were seen with subsequent attacks. Conclusions This constellation of symptoms and imaging findings is suggestive of reversible cerebral vasoconstriction syndrome, which we propose as a mechanism for the transient ischemic attacks and infarcts seen in some patients with Schimke immuno-osseous dysplasia, as opposed to accelerated atherosclerosis alone. This new insight may provide a basis for novel preventative therapy in this rare disorder.
2016-11-05 | Increased Wnt and Notch signaling: a clue to the renal disease in Schimke immuno-osseous dysplasia?
Schimke immuno-osseous dysplasia (SIOD) is a multisystemic disorder caused by biallelic mutations in the SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily A-like 1 (SMARCAL1) gene. Changes in gene expression underlie the arteriosclerosis and T-cell immunodeficiency of SIOD; therefore, we hypothesized that SMARCAL1 deficiency causes the focal segmental glomerulosclerosis (FSGS) of SIOD by altering renal gene expression. We tested this hypothesis by gene expression analysis of an SIOD patient kidney and verified these findings through immunofluorescent analysis in additional SIOD patients and a genetic interaction analysis in Drosophila. We found increased expression of components and targets of the Wnt and Notch signaling pathways in the SIOD patient kidney, increased levels of unphosphorylated β-catenin and Notch1 intracellular domain in the glomeruli of most SIOD patient kidneys, and genetic interaction between the Drosophila SMARCAL1 homologue Marcal1 and genes of the Wnt and Notch signaling pathways. We conclude that increased Wnt and Notch activity result from SMARCAL1 deficiency and, as established causes of FSGS, contribute to the renal disease of most SIOD patients. This further clarifies the pathogenesis of SIOD and will hopefully direct potential therapeutic approaches for SIOD patients.
gene therapies
2026-08-20 | Beyond Defense: Kidney Mysteries in Inborn Errors of Immunity
Inborn errors of immunity (IEI), formerly termed primary immunodeficiencies, are increasingly recognized as disorders of immune dysregulation rather than infection susceptibility alone. With over 500 validated genes in the 2024 International Union of Immunological Societies (IUIS) classification and approximately one-quarter of patients presenting without infection, autoimmunity, autoinflammation, lymphoproliferation, and malignancy are now core features. The kidney is affected across at least 22 IEI categories, yet renal involvement remains under-recognized. This review proposes a mechanistic framework for IEI-associated kidney disease, encompassing: complement dysregulation (C3 glomerulopathy, atypical hemolytic uremic syndrome from CFH/CFI/C3 variants); immune complex–mediated and monogenic lupus nephritis (C1q, C2, C4, DNASE1L3, and TREX1 defects); autoinflammatory and type I interferonopathy–driven nephropathy; infection-related glomerulonephritis (common variable immunodeficiency [CVID], chronic granulomatous disease); lymphoproliferative and immune-dysregulation syndromes causing interstitial nephritis (ALPS, CTLA-4 and LRBA deficiency); and syndromic IEI with intrinsic structural disease. We outline a stepwise diagnostic approach integrating clinical red flags, complement and immune profiling, kidney biopsy with immunofluorescence and electron microscopy, and genetic testing, emphasizing that genetic diagnosis should precede immunosuppression. The therapeutic landscape is shifting from empirical immunosuppression toward precision medicine, including complement inhibitors (iptacopan, pegcetacoplan, Food and Drug Administration–approved for C3 glomerulopathy in 2025), JAK inhibitors for interferonopathies, leniolisib for activated PI3Kδ syndrome, CTLA4-Ig agents, and curative hematopoietic stem cell transplantation and emerging gene therapy. An illustrative case from Europe’s largest kidney transplant center illustrates a girl with Schimke immuno-osseous dysplasia (SMARCAL1 mutation) presenting with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis who underwent kidney transplantation following bone marrow transplant. Recognizing IEI in unexplained nephropathy, combining biopsy with complement and genetic profiling, and early nephrology–immunology collaboration are key to improving renal outcomes and enabling potentially curative therapy.
2026-03-06 | Genetic alterations in Schimke immunoosseous dysplasia: Pathogenic mechanisms and therapeutic prospects
Schimke immuno-osseous dysplasia (SIOD) is an ultra-rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in SMARCAL1, which encodes an adenosine triphosphate-dependent annealing helicase involved in replication-fork remodeling and chromatin dynamics. Loss of SMARCAL1 function leads to replication-associated genomic instability, transcriptional dysregulation, and telomere dysfunction, collectively underlying the triad of steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency, as well as vascular and malignant complications. In this review, we summarize the spectrum of SMARCAL1 genetic alterations in SIOD, ranging from missense and truncating variants to gross deletions, and discuss their molecular consequences at the protein and cellular levels. We highlight current disease models, including patient-derived induced pluripotent stem cells (iPSCs) and inducible SMARCAL1 knockdown iPSC systems, which have revealed mechanistic links between replication stress and dysregulated expression of master differentiation genes. Finally, we evaluate the state of the art and realistic prospects for gene therapy in SIOD. Although no gene therapy trial for SIOD is currently active, advances in iPSC modeling, clustered regularly interspaced short palindromic repeats-mediated gene correction, and successful ex vivo hematopoietic stem cell gene therapy in related monogenic immunodeficiencies position SMARCAL1 as a plausible, though challenging, therapeutic target. Key obstacles include multi-organ involvement, strict control of SMARCAL1 dosage due to its role in genome stability, and the extreme rarity of the disorder, which limits the feasibility of clinical trials.
2025-02-26 | Genetic and Clinical Features of Schimke Immuno-Osseous Dysplasia: Single-Centre Retrospective Study of 21 Unrelated Paediatric Patients over a Period of 20 Years.
Schimke immuno-osseous dysplasia (SIOD) is a hereditary autosomal-recessive multi-system disorder with early mortality. It has variable clinical presentations, mainly characterised by disproportional short stature, steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency. In the majority of cases, SIOD is caused by pathogenic sequence variants (PSVs) in the SMARCAL1 gene that encodes protein involved in chromatin remodelling. SIOD is an ultra-rare condition, with an incidence of ~1 per 1-3 million live births; data on its genetic and clinical features are scarce. We conducted a retrospective study of 21 paediatric patients with SIOD diagnosed in our centre during the years 2003-2023. The most common extra-renal clinical features were short stature, osseous dysplasia, multiple stigmas, and leukopenia. Proteinuria of varying severity was observed in 16 cases. The five-year overall survival rate (OS) was 89% (95% CI 77-100%), and the ten-year OS was 10%. Next-generation sequencing (NGS) revealed the following PSVs in SMARCAL1 in 19 patients: c.355_500del, c.2542G>T, c.2290C>T, c.2562del, c.2533_2534del, c.1582A>C, c.1933C>T, c.1010T>C, c.1736C>T, c.2070dup, c.2551A>T, c.2149_2150dup, c.939delC, and c.1451T>A; the most common was c.2542G>T, resulting in premature translation termination (p.E848*), and it was found in 14 patients either in a homozygous (four patients) or compound-heterozygous (10 patients) state. According to microsatellite analysis, it is a "founder mutation" in Russia.
2010-05-01 | SMARCAL1 and replication stress
The SNF2 family of ATPases acts in the context of chromatin to regulate transcription, replication, repair, and recombination. Defects in SNF2 genes cause many human diseases. For example, mutations in SMARCAL1 (also named HARP) cause Schimke immuno-osseous dysplasia (SIOD); a multi-system disorder characterized by growth defects, immune deficiencies, renal failure and other complex phenotypes. Several groups including ours recently identified SMARCAL1 as a replication stress response protein. Importantly, SMARCAL1 localizes to stalled replication forks and this localization of SMARCAL1 activity prevents DNA damage accumulation during DNA replication. We determined that SIOD-related SMARCAL1 mutants could not prevent replication-associated DNA damage in cells in which endogenous SMARCAL1 was silenced, establishing the first link between SIOD and a defect in a specific biological activity. Here, we also report that cells from patients with SIOD exhibit elevated levels of DNA damage that can be rescued by re-introduction of wild-type SMARCAL1. Our data suggest that loss of SMARCAL1 function in patients may cause DNA replication-associated genome instability that contributes to the pleiotropic phenotypes of SIOD.
antibodies
2026-01-01 | When rarity meets complexity - Schimke immuno-osseous dysplasia with nephrotic syndrome: a 15-year longitudinal case report
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder caused by pathogenic variants in the SMARCAL1 gene and characterised by spondyloepiphyseal dysplasia, immunodeficiency, and progressive renal disease, often presenting as steroid-resistant nephrotic syndrome.Fewer than 100 cases have been reported worldwide.This manuscript describes a male patient with genetically confirmed SIOD, monitored age 4.5-19 years.Early features included growth failure, hyperpigmentation, skeletal abnormalities, moderate T-cell lymphopaenia, and biopsy-proven focal segmental glomerulosclerosis.In adolescence, the disease transitioned to a severe phenotype with end-stage renal disease, recurrent infections, bone marrow failure, and Evans syndrome, reflecting profound immune dysregulation.Despite multidisciplinary management, including renal-replacement therapy and individualised immunological care, the patient's condition progressively deteriorated and he ultimately died from multi-organ failure.This long-term observation illustrates the evolving natural history of SIOD and the shift from renal disease in childhood to combined immunodeficiency and haematological complications in adolescence.
2025-12-26 | Clinical and genetic characteristics of Schimke immuno-osseous dysplasia in Russian children: a single-centre study
.
2025-06-11 | Schimke immune-osseous dysplasia at the junction of specialties. A clinical case of disease diagnosis by allergologists and immunologists
Introduction. Schimke immuno-osseous dysplasia (SIOD) is an autosomal recessive, ultrarare disorder characterized by multisystem involvement accompanied by spondyloepiphyseal dysplasia of the skeleton, steroid-resistant proteinuric nephropathy leading to progressive loss of renal function, impaired immunity, and vascular damage caused by atherosclerosis. SIOD is caused by biallelic pathogenic variations in the SMARCAL1 gene.The clinical manifestations of SIOD are very diverse: from a rapidly progressive disease in which children die in the first years of life, to milder forms in which they survive to adulthood. The correlation between genotype and phenotype is extremely weak, so it is impossible to predict either the clinical course or the outcome of the disease. For this reason, patients with this pathology can be seen by various specialists. Case report. The publication presents a clinical case of a 4-year-old boy with immunological deficiency, developmental disorders, and skeletal anomalies, indicating in favor of SIOD.Whole exome sequencing in the SMARCAL1 gene revealed mutation variants с.2542G>T (p.Glu848Ter); c.1682G>T (p.Arg561Leu) in a heterozygous state.Based on the results of the genetic study, and also taking into account that the disease is multisystemic, the child was examined by a nephrologist, orthopedist, endocrinologist and geneticist.Conclusions of the nephrologist: glomerulopathy in Schimke syndrome: isolated proteinuria. Left calicectasis. Chronic kidney disease (CKD), stage 2. Glomerular filtration rate (Schwartz test) — 69.01 ml/min/1.73 m2.Endocrinologist’s conclusion: syndromic short stature. Protein-energy malnutrition grade 2.A telemedicine consultation was conducted with the Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology and Oncology named after D. Rogachev, based on the results of which replacement therapy with intravenous or subcutaneous immunoglobulins was recommended, as well as hospitalization in the immunology department of this federal center. Conclusion. This description is the first case of diagnostics of an ultrarare disease (1:1–3,000,000 live births) in Krasnodar region by regional specialists. In this patient, the course of the disease is characterized by a non-severe, non-progressive renal dysfunction, which gives reason to assume a milder form of the disease. Conducting replacement therapy with immunoglobulins makes it possible to improve the prognosis in this patient.
2021-05-31 | Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency.
Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency. We report 2 patients with BCP-ALL and congenital T-cell immunodeficiency, who obtained an excellent response to blinatumomab. The first, a 6-year-old girl with Schimke immuno-osseous dysplasia (SIOD) and combined immunodeficiency disorder (CID) obtained a minimum residual disease-negative (MRD-) remission of high hyperdiploid BCP-ALL with blinatumomab. At last follow-up, the remission had been sustained for 14 months from diagnosis. The second was a 9-year-old boy with Omenn syndrome and CID who received a mismatched bone marrow transplant from his mother at the age of 4 months and was diagnosed with t(3;11)+ (KMT2A-LARS2) BCP-ALL 9 years after his transplant. He received a 4-drug induction followed by blinatumomab for persistent MRD as a chemotherapy-sparing bridge to transplant and achieved an MRD- remission. T-lymphopenia, whether congenital or acquired, does not compromise the efficacy of blinatumomab.
other
2025-11-09 | A novel gross deletion in SMARCAL1 impairs DNA replication fork regression, leading to severe Schimke immuno-osseous dysplasia; a literature review and an integrated study of clinical, genetic, and protein-protein interaction analysis
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder that affects multiple organ systems, most notably the skeletal system, kidneys, and immune system. The clinical manifestations of SIOD include growth retardation, skeletal deformities, progressive proteinuria, and immunodeficiency. Severe cases may progress to nephrotic syndrome and cerebral infarctions. The disorder is primarily attributed to biallelic mutations in the SMARCAL1 gene, which leads to the early onset of symptoms and often results in premature mortality. In this study, we identified a novel gross deletion encompassing exons 5 and 6 of the SMARCAL1 gene. This deletion leads to a partial loss of the HARP1 and HARP2 domains and the generation of a novel HARP domain that is structurally similar to both HARP1 and HARP2, while retaining conserved amino acids. Our AlphaFold 3D modeling indicated that the truncated SMARCAL1 protein is identical to the wild-type SMARCAL1, except for the absence of HARP1 domain, and resembles invertebrate SMARCAL1, which naturally possesses only one HARP domain. Previous studies have demonstrated that human SMARCAL1 lacking the HARP1 domain retains normal helicase, ATPase, and DNA-binding activities. Additionally, invertebrate SMARCAL1, which also lacks the HARP1 domain, fails to effectively regress DNA replication forks. This suggests that the identified gross deletion may contribute to SIOD pathogenesis by impairing DNA replication fork regression and genomic instability
2024-09-18 | Different growth patterns in two siblings with Schimke immuno-osseous-dysplasia.
Schimke immuno-osseous-dysplasia (SIOD) is an autosomal recessive systemic disease due to pathogenic variants in SMARCAL1. Manifestations include nephrotic syndrome (NS), kidney failure, T-cell dysfunction, vaso-occlusive disease, and disproportionate short stature, a general feature of this disease. Here, we present a markedly different growth pattern in two brothers with SIOD sharing the same homozygous R561C missense variant. The index patient presented at the age of 11 years with NS and severely disproportionate short stature, followed by kidney failure at the age of 16, and severely reduced adult height (z-score - 8.0). In contrast, the younger brother showed normal growth until the age of 8 years. Mild proteinuria was noted at the age of 4.5, followed by NS at 9.5 years, kidney failure at 11 years, progressive disproportionate stature, and reduced adult height (z-score - 4.5). Both brothers had comparable disproportion in adulthood (sitting height index z-score - 0.88 and - 1.44, respectively).
2024-08-08 | Expanding the Clinical Features of Schimke Immuno-osseous Dysplasia: a New Patient with a Novel Variant and Novel Clinical Findings.
Schimke immuno-osseous dysplasia (SIOD) (MIM:242900) is an ultra-rare, autosomal recessive, pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency, spondyloepiphyseal dysplasia (SED) and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-a-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia, and elevated follicle-stimulating hormone (FSH) levels. Karyotype analysis and array-CGH testing were normal. Clinical exome sequencing (CES) was performed to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious SED was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. The literature on SMARCAL1 gene pathogenic variants, including 125 SIOD cases from 38 articles was reviewed to investigate whether hypercalcemia, hypophosphatemia, and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first report of these findings in a patient with SIOD. Thus, this report expands both the phenotypic and genotypic spectrum of SIOD.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.